Abstract
Get full access to this article
View all access options for this article.
References
1.
Stein
R
. Gene therapy shows promise for hemophilia,
but could be most expensive
U.S
. drug ever. NPR. 2020. https://www.npr.org/sections/health-shots/2020/07/20/800556057/gene-therapy-shows-promise-for-hemophilia-but-could-be-most-expensive-u-s-drug-e (last accessed
July 31 , 2020
).
2.BioMarin Pharmaceutical. BioMarin provides additional data from recent 4 year update of ongoing phase 1/2 study of valoctocogene roxaparvovec gene therapy for severe hemophilia A in late-breaking oral presentation at World Federation of Hemophilia Virtual Summit. 2020 . https://investors.biomarin.com/2020-06-17-BioMarin-Provides-Additional-Data-from-Recent-4-Year-Update-of-Ongoing-Phase-1-2-Study-of-Valoctocogene-Roxaparvovec-Gene-Therapy-for-Severe-Hemophilia-A-in-Late-Breaking-Oral-Presentation-at-World-Federation-of-Hemophilia-Virtual-Summit (last accessed
July 31 , 2020
).
3.Sangamo Therapeutics and Novartis. Sangamo announces global collaboration with novartis to develop genomic medicines for autism and other neurodevelopmental disorders. 2020 . https://investor.sangamo.com/news-releases/news-release-details/sangamo-announces-global-collaboration-novartis-develop-genomic (last accessed
July 31 , 2020
).
4.Encoded Therapeutics. Encoded therapeutics announces $135 million series d financing to support first clinical trials in SCN1A+ Dravet syndrome and advance preclinical pipeline of gene therapies for debilitating neurological disorders. 2020 . https://encoded.com/encoded-therapeutics-announces-135-million-series-d-financing-to-support-first-clinical-trials-in-scn1a-dravet-syndrome-and-advance-preclinical-pipeline-of-gene-therapies-for-debilitating-neurologic/ (last accessed
July 31 , 2020
).
5.
Wilson
JM
,
Flotte
TR
. Moving forward after two deaths in a gene therapy trial of myotubular myopathy. Genetic Engineering &
Biotechnology
News
. 2020. https://www.genengnews.com/commentary/moving-forward-after-two-deaths-in-a-gene-therapy-trial-of-myotubular-myopathy/ (last accessed
July 30 , 2020
).
6.U.K. Government. Over £100 million cash boost to manufacture millions of doses of COVID-19 vaccine. 2020 . https://www.gov.uk/government/news/over-100-million-cash-boost-to-manufacture-millions-of-doses-of-covid-19-vaccine (last accessed
July 31 , 2020
).
7.
Orchard
Therapeutics
.
Orchard therapeutics announces global license agreements for stable cell line technology from
GSK
. 2020. https://ir.orchard-tx.com/news-releases/news-release-details/orchard-therapeutics-announces-global-license-agreements-stable (last accessed
July 31 , 2020
).
8.XyloCor Therapeutics. XyloCor therapeutics doses patients in phase 1/2 trial evaluating novel gene therapy XC001 in refractory Angina. 2020 . https://www.businesswire.com/news/home/20200721005293/en/XyloCor-Therapeutics-Doses-Patients-Phase-12-Trial (last accessed
July 31 , 2020
).